QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pa...(hine or oxycodone every 6 hours for 48 h...),Health

Date:4/20/2009

hine or oxycodone every 6 hours for 48 hours. The study's primary clinical endpoint was changes in the pain intensity scores from baseline for MoxDuo(TM) IR versus component doses of morphine and oxycodone alone. Secondary endpoints included: (1) pain relief and global assessment of effect; and (2) safety as measured by the incidence and intensity of opioid-related adverse events.

In terms of reduced pain intensity scores and other related measures, the analgesic effects of 12mg/8mg MoxDuo(TM) IR were 80-100% greater than the components, morphine or oxycodone. The 6mg/4mg MoxDuo(TM) IR dose also showed similar improvements when compared to its individual components.

Significantly, the frequency of moderate to severe adverse events (including nausea, vomiting, constipation, dizziness, etc.) was 25% to 75% lower among patients on MoxDuo(TM) IR compared to those receiving equi-analgesic doses of morphine or oxycodone alone. Furthermore, patients receiving morphine or oxycodone alone were two to four times more likely to prematurely discontinue dosing than those on MoxDuo(TM) IR.

"These data indicate that MoxDuo(TM) IR has the potential to provide superior pain relief with a lower frequency and severity of side effects when compared to either morphine or oxycodone," said Holaday. "The improved tolerability profile should enable pain practitioners to prescribe higher doses of MoxDuo(TM) IR to achieve better pain relief with fewer side effects than morphine or oxycodone alone."

Additional studies evaluating MoxDuo(TM) IR versus Percocet(R) in patients with joint replacement surgery are underway, with results expected in Q3 of 2009.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These
'/>"/>

SOURCE QRxPharma Limited Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
4. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
5. MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
6. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
7. Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children
8. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
9. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
10. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
11. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol